How Do GLP-1 Drugs Work?
How do GLP-1 drugs work? They act like GLP-1, a hormone your body makes, by turning on the GLP-1 receptor. People also call them GLP-1 medications.
Paste this code into your page. It shows the GLP-1 comparison chart with one plain credit link.
Learn
More about this page
Every FDA label has a section called 12.1, Mechanism of Action. This page explains what those sections say, in plain words. The exact words are in the tables.
GLP-1, the body's own hormone
GLP-1 is a hormone. The gut releases it into the blood, the Byetta label says. A 2018 review in Cell Metabolism adds that it acts around meals. It boosts insulin, lowers glucagon, and slows stomach emptying and food intake. It acts on the GLP-1 receptor, which is found on cells in the body and the brain.
The body's own GLP-1 does not last long. Enzymes break it down within minutes, the Saxenda label says. The medicines are built to last much longer. For example, semaglutide binds to albumin, a blood protein, which slows its clearance.
Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.
Blood sugar: insulin and glucagon
The labels for type 2 diabetes describe three actions.
- More insulin when sugar is high. The medicine helps the pancreas release insulin. It does this mainly when blood sugar is high.
- Less glucagon. The medicine lowers glucagon, another hormone, also mainly when blood sugar is high.
- Slower stomach emptying. Several labels say the medicine slows how fast food leaves the stomach.
Appetite
The labels for the weight medicines add a fourth point. GLP-1 helps control appetite and how much you eat. GLP-1 receptors sit in brain areas that control appetite. In animal studies, the medicines reached those brain areas.
Tirzepatide: GIP and GLP-1
Tirzepatide acts on two receptors: GIP and GLP-1. GIP is another hormone the body makes. Early lab and animal studies suggest GIP may add to the control of food intake, the Zepbound label says. For how the brands compare, see tirzepatide vs semaglutide.
Insulin mixes
Xultophy and Soliqua each mix a GLP-1 medicine with an insulin. Their labels explain both parts. The insulin part lowers blood sugar by helping muscle and fat take up sugar, and by cutting sugar made by the liver.
In each label's own words
| Topic | Label | Section 12.1 says |
|---|---|---|
| GLP-1 comes from the gut | Byetta | Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. |
| Blood sugar | Ozempic | Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated, and glucagon secretion is inhibited. |
| Stomach emptying | Trulicity | Dulaglutide also decreases glucagon secretion and slows gastric emptying. |
| Appetite | Wegovy | GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. |
| The added GIP target | Zepbound | Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. |
| Why the body's own GLP-1 does not last | Saxenda | Endogenous GLP-1 has a half-life of 1.5 to 2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidases (NEP). |
| How semaglutide lasts longer | Ozempic | The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. |
| A tablet that is not semaglutide | Foundayo | FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. |
| Insulin mixes | Xultophy | Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. |
| What is not known | Ozempic | The mechanism of kidney-related risk reduction has not been established. |
| What is not known | Wegovy | The exact mechanism of semaglutide in CV risk reduction in adults has not been established. |
Every brand's section 12.1, one line each:
| Brand | Medicine | Type | Label section 12.1 says | Label version |
|---|---|---|---|---|
| Ozempic | semaglutide | GLP-1 | Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. | v20, June 1, 2026 |
| Wegovy | semaglutide | GLP-1 | GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. | v19, June 18, 2026 |
| Rybelsus and Ozempic tablets | semaglutide | GLP-1 | Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. | v14, January 30, 2026 |
| Mounjaro | tirzepatide | GIP and GLP-1 | Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. | v40, August 27, 2026 |
| Zepbound | tirzepatide | GIP and GLP-1 | GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. | v40, August 28, 2026 |
| Foundayo | orforglipron | GLP-1 | FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. | v10, July 29, 2026 |
| Saxenda | liraglutide | GLP-1 | Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor | v22, February 25, 2026 |
| Victoza | liraglutide | GLP-1 | Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. | v31, October 14, 2025 |
| Trulicity | dulaglutide | GLP-1 | Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying. | v62, June 16, 2026 |
| Byetta | exenatide | GLP-1 | BYETTA is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. | v26, September 2, 2025 |
| Xultophy | insulin degludec and liraglutide | Insulin plus GLP-1 | Liraglutide is a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying. | v14, October 14, 2025 |
| Soliqua | insulin glargine and lixisenatide | Insulin plus GLP-1 | Lixisenatide is a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying. | v25, March 18, 2026 |
What the labels say is not known
Some labels say plainly that part of the mechanism is not known. The Ozempic label says how it lowers kidney risk has not been established. The Wegovy label says the same about its cardiovascular risk reduction. This site does not fill those gaps.
For every brand in one place, see the GLP-1 comparison chart or the list of GLP-1 drugs.
Questions
What is a GLP-1 drug?
A GLP-1 drug is a medicine that acts like GLP-1, a hormone the gut releases into the blood. It turns on the GLP-1 receptor. The labels call these medicines GLP-1 receptor agonists.
What do GLP-1 drugs do?
GLP-1 drugs turn on the GLP-1 receptor, like the body's own GLP-1. The labels say this helps release insulin and lower glucagon when blood sugar is high. Several labels also say they slow stomach emptying.
What is the GLP-1 receptor agonist mechanism of action?
An agonist is a medicine that turns on a receptor. GLP-1 receptor agonists bind to the GLP-1 receptor and turn it on. The labels describe the effects on insulin, glucagon, the stomach and appetite.
How do GLP-1 drugs work for weight loss?
The weight labels say GLP-1 helps control appetite and how much a person eats. GLP-1 receptors are in brain areas that control appetite. The labels do not claim more than that about how they work.
Sources
9 sources with read dates
- Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
- Wegovy label on DailyMed, Novo Nordisk, version 19 of 2026-06-18, read 2026-10-06
- Zepbound label on DailyMed, Eli Lilly, version 40 of 2026-08-28, read 2026-10-06
- Saxenda label on DailyMed, Novo Nordisk, version 22 of 2026-02-25, read 2026-10-06
- Trulicity label on DailyMed, Eli Lilly, version 62 of 2026-06-16, read 2026-10-06
- Byetta label on DailyMed, AstraZeneca, version 26 of 2025-09-02, read 2026-10-06
- Foundayo label on DailyMed, Eli Lilly, version 10 of 2026-07-29, read 2026-10-06
- Xultophy label on DailyMed, Novo Nordisk, version 14 of 2025-10-14, read 2026-10-06
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06